Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease
Authors
- K.M. Kortüm
- C. Langer
- J. Monge
- L. Bruins
- J.B. Egan
- Y.X. Zhu
- C.X. Shi
- P. Jedlowski
- J. Schmidt
- J. Ojha
- L. Bullinger
- P. Liebisch
- M. Kull
- M.D. Champion
- S. Van Wier
- G. Ahmann
- L. Rasche
- S. Knop
- R. Fonseca
- H. Einsele
- A.K. Stewart
- E. Braggio
Journal
- British Journal of Haematology
Citation
- Br J Haematol 168 (4): 507-510
Abstract
We constructed a multiple myeloma (MM)-specific gene panel for targeted sequencing and investigated 72 untreated high-risk (del17p) MM patients. Mutations were identified in 78% of the patients. While the majority of studied genes were mutated at similar frequency to published literature, the prevalence of TP53 mutation was increased (28%) and no mutations were found in FAM46C. This study provides a comprehensive insight into the mutational landscape of del17p high-risk MM. Additionally, our work demonstrates the practical use of a customized sequencing panel, as an easy, cheap and fast approach to characterize the mutational profile of MM.